Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 18/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.55 |
| ▸ | HCK | P08631 | 1/20 | 0.52 |
| ▸ | NR2C2 | P49116 | 1/20 | 0.52 |
| ▸ | BTK | Q06187 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | RAF1 | P04049 | 1/20 | 0.51 |
| ▸ | YES1 | P07947 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL827485 | 0.81 | MEN1 (0.62) | BRAFCYP2C9 | |
| SCHEMBL29877734 | 0.81 | BRAF (0.56) | BRAFCYP2C9RAF1YES1 | |
| SCHEMBL2196658 | 0.81 | BRAF (0.66) | BRAFCYP2C9RAF1YES1 | |
| SCHEMBL2191947 | 0.81 | BRAF (0.52) | BRAFCYP2C9HCKNR2C2BTK | |
| SCHEMBL14819854 | 0.81 | BRAF (0.69) | BRAFCYP2C9RAF1YES1 | |
| SCHEMBL1698068 | 0.80 | BRAF (0.65) | BRAFCYP2C9RAF1YES1 | |
| SCHEMBL18196115 | 0.80 | BRAF (0.75) | BRAFCYP2C9HCKNR2C2BTK | |
| SCHEMBL26075765 | 0.80 | BRAF (0.54) | BRAFCYP2C9GAARAF1 | |
| SCHEMBL20577960 | 0.79 | BRAF (0.59) | BRAFCYP2C9RAF1YES1 | |
| SCHEMBL1697890 | 0.79 | BRAF (0.59) | BRAFCYP2C9RAF1YES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2184285-B1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2015-11-04 | — | — | EP | disclosed |
| EP-2181987-B9 | 2-Carbonylaminobenzothiazoles and their use for the prophylaxis and treatment of cancer | TAKEDA PHARMACEUTICAL (JP) | 2014-09-03 | — | — | EP | disclosed |
| EP-2181987-B1 | 2-Carbonylaminobenzothiazoles and their use for the prophylaxis and treatment of cancer | TAKEDA PHARMACEUTICAL (JP) | 2014-03-05 | — | — | EP | disclosed |
| US-8344135-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-01-01 | — | — | US | disclosed |
| US-8324395-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-12-04 | — | — | US | disclosed |
| US-20110172245-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-14 | — | — | US | disclosed |
| US-20100249119-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-30 | — | — | US | disclosed |
| EP-2184285-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2010-05-12 | — | — | EP | disclosed |
| EP-2181987-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2010-05-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172245-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | BRAF, NRAS, RAF1 | BRAF 1/4885CYP2C9 1933/4885HCK 742/4885 |
| US-20100249119-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | BRAF, NRAS, RAF1 | BRAF 1/4885CYP2C9 2054/4885HCK 858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.